RHY 4.11% 7.0¢ rhythm biosciences limited

CRC Blood Tests: A Future Without Screening Colonoscopies?, page-5

  1. 280 Posts.
    lightbulb Created with Sketch. 95
    This morning I scanned the ASCO Annual Meeting abstracts for CRC screening test research to check the competition in this field.

    Of the 96 relevant study abstracts, there are two other similar non-DNA tests, however neither are as good as Colostat.

    One in UK which relies on Spectroscopic processing and has relatively low sensitivity of 74%.

    Another from China requires tissue samples to be extracted from the bowel/gut.

    Colostat is something of a shining beacon amongst the cohort! It's also very positive that the ASCO website publishes the selected abstracts in a clear, concise, easy to read, and comparable format. Anyone can access them, anywhere in the world.

    My impression is that Rhythm are targeting the attention of US insurance companies with these two abstracts, in particular the economic modelling abstract. Both are extremely impressive to read, with carefully chosen wording, details and statistics. Go Trevor!!
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.